Roche's (RHHBY.US) Gouffran new indications approved in China

According to the Wisdom Financial APP, on May 7th, Roche (RHHBY.US) announced that the new indication for the injection of Glofitamab has been approved by the National Medical Products Administration (NMPA) in China. It is approved for use in combination with Gemcitabine and Oxaliplatin (GemOx) for the treatment of relapsed or refractory diffuse large Bcell lymphoma nonspecified type (DLBCL NOS) adult patients who are not suitable for autologous hematopoietic stem cell transplant (ASCT). Glofitamab (Columvi) is a bispecific T-cell engaging protein targeting CD20 and CD3.